Hokom M - Search Results

1

Bioanalytical challenges in development of ultrasensitive Home Brew assays: a case study using IL-13.

Sperinde G, Hokom M, Peng K, Fischer SK. Sperinde G, et al. Among authors: hokom m. Bioanalysis. 2019 Jun;11(11):1045-1054. doi: 10.4155/bio-2019-0012. Bioanalysis. 2019. PMID: 31251105

2

Challenges with development of a pharmacokinetics assay to measure a variably glycosylated fusion protein.

Sperinde G, Liu L, Xu K, Bentley T, Sukumaran S, Lutman J, Huang C, Williams K, Hokom M, Fischer SK. Sperinde G, et al. Among authors: hokom m. Bioanalysis. 2022 Jan;14(1):7-18. doi: 10.4155/bio-2021-0186. Epub 2021 Nov 18. Bioanalysis. 2022. PMID: 34789009

3

Considerations for Soluble Protein Biomarker Blood Sample Matrix Selection.

Mathews JA, Ni YG, Wang C, Peterson JE, Ray C, Zhao X, Duan D, Hamon S, Allinson J, Hokom M, Wegner G. Mathews JA, et al. Among authors: hokom m. AAPS J. 2020 Jan 29;22(2):38. doi: 10.1208/s12248-020-0412-0. AAPS J. 2020. PMID: 31997095 Review.

4

Identification and inhibition of drug target interference in immunogenicity assays.

Zhong ZD, Dinnogen S, Hokom M, Ray C, Weinreich D, Swanson SJ, Chirmule N. Zhong ZD, et al. Among authors: hokom m. J Immunol Methods. 2010 Apr 15;355(1-2):21-8. doi: 10.1016/j.jim.2010.02.008. Epub 2010 Feb 24. J Immunol Methods. 2010. PMID: 20188106

5

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects.

Jawa V, Hokom M, Hu Z, El-Abaadi N, Zhuang Y, Berger D, Gupta S, Swanson SJ, Chirmule N. Jawa V, et al. Among authors: hokom m. Ann Hematol. 2010 Jul;89 Suppl 1(Suppl 1):75-85. doi: 10.1007/s00277-010-0908-2. Epub 2010 Feb 13. Ann Hematol. 2010. PMID: 20155267 Free PMC article.

6

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.

Cohen JR, Brych SR, Prabhu S, Bi V, Elbaradei A, Tokuda JM, Xiang C, Hokom M, Cui X, Ly C, Amos N, Sun J, Calamba D, Herskovitz J, Capili A, Nourbakhsh K, Merlo A, Carreon J, Wypych J, Narhi LO, Jawa V, Joubert MK. Cohen JR, et al. Among authors: hokom m. Pharm Res. 2024 Apr;41(4):651-672. doi: 10.1007/s11095-024-03678-2. Epub 2024 Mar 22. Pharm Res. 2024. PMID: 38519817

7

Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T. Bi V, et al. Among authors: hokom m. J Pharm Sci. 2013 Oct;102(10):3545-55. doi: 10.1002/jps.23663. Epub 2013 Aug 7. J Pharm Sci. 2013. PMID: 23925953

8

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. Joubert MK, et al. Among authors: hokom m. J Biol Chem. 2012 Jul 20;287(30):25266-79. doi: 10.1074/jbc.M111.330902. Epub 2012 May 14. J Biol Chem. 2012. PMID: 22584577 Free PMC article.

9

Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor.

Hunt P, Li YS, Nichol JL, Hokom MM, Bogenberger JM, Swift SE, Skrine JD, Hornkohl AC, Lu H, Clogston C, et al. Hunt P, et al. Among authors: hokom mm. Blood. 1995 Jul 15;86(2):540-7. Blood. 1995. PMID: 7541666 Free article.

10

The effect of the platelet-derived glycosaminoglycan serglycin on in vitro proplatelet-like process formation.

Hunt P, Hokom MM, Hornkohl A, Wiemann B, Rohde MF, Arakawa T. Hunt P, et al. Among authors: hokom mm. Exp Hematol. 1993 Aug;21(9):1295-304. Exp Hematol. 1993. PMID: 8330653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters